Why GLP-1 Non-Responders Need Earlier Anti-Obesity Medication Intervention Introduction GLP-1 non-responders represent a critical challenge in obesity management that requires prompt medical intervention. Despite the availability of six FDA-approved anti-obesity medications (AOMs) for chronic weight management, current guidelines recommend waiting six months after behavioral therapy
Tag: #TreatmentResistance
Tachyphylaxis in Antidepressants: The Science Behind Treatment Resistance
Tachyphylaxis in Antidepressants: The Science Behind Treatment Resistance Introduction Tachyphylaxis is a challenging phenomenon that occurs when antidepressant medications gradually lose their therapeutic efficacy despite continued administration at the same dosage. The prevalence of antidepressant treatment tachyphylaxis is substantial, affecting approximately 25 percent of treated,
